These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 7510220)

  • 1. Role of prostate specific antigen (PSA) and carcinoembryonic antigen (CEA) in screening for prostate and recurrent colon cancers in the elderly.
    Vandenberg TA
    Clin Biochem; 1993 Dec; 26(6):429-30. PubMed ID: 7510220
    [No Abstract]   [Full Text] [Related]  

  • 2. Serum mucin antigens CASA and MSA in tumors of the breast, ovary, lung, pancreas, bladder, colon, and prostate. A blind trial with 420 patients.
    Devine PL; McGuckin MA; Ramm LE; Ward BG; Pee D; Long S
    Cancer; 1993 Sep; 72(6):2007-15. PubMed ID: 7689923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relapsed prostate cancer with neuroendocrine differentiation and high serum levels of carcinoembryonic antigen without elevation of prostrate-specific antigen: a case report.
    Kinebuchi Y; Noguchi W; Irie K; Nakayama T; Kato H; Nishizawa O
    Int J Urol; 2007 Feb; 14(2):147-9. PubMed ID: 17302572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring of Serum Carcinoembryonic Antigen Levels after Curative Resection of Colon Cancer: Cutoff Values Determined according to Preoperative Levels Enhance the Diagnostic Accuracy for Recurrence.
    Saito G; Sadahiro S; Kamata H; Miyakita H; Okada K; Tanaka A; Suzuki T
    Oncology; 2017; 92(5):276-282. PubMed ID: 28178692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Markers of undiagnosed incidental cancer in comparison with clinical prostatic cancer.
    Ogawa A; Yoshida A; Kanda T; Sugihara S; Suzuki T; Tamura J; Kobayashi I; Nakazato Y
    J Med; 2000; 31(1-2):101-10. PubMed ID: 10998759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Recrudescence of prostate cancer with low serum level of PSA and high serum level of CEA and CA19-9: a case report].
    Yokoyama S; Fukuhara S; Imazu T; Hara T; Yamaguchi S; Adachi S
    Hinyokika Kiyo; 2007 Jul; 53(7):485-7. PubMed ID: 17702183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple tumor marker elevation in androgen ablation-refractory prostate cancer with long-term response to metronomic chemotherapy: a case report.
    Massaccesi M; Forni F; Spagnuolo P; Macchia G; Mignogna S; De Ninno M; Cellini N; Giardina B; Carbone A; Morganti AG
    Int J Biol Markers; 2010; 25(4):243-7. PubMed ID: 21161947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PSA and the detection of prostate cancer.
    Robbins AS
    JAMA; 1994 Jan; 271(3):192-3. PubMed ID: 7506314
    [No Abstract]   [Full Text] [Related]  

  • 9. CEA for monitoring colon cancer.
    Chu DZ; Ellenhorn JD; Paz IB; Wagman LD; Williams WL
    JAMA; 1994 Feb; 271(5):345-6; author reply 346-7. PubMed ID: 8283579
    [No Abstract]   [Full Text] [Related]  

  • 10. Relation between Carcinoembryonic Antigen Levels in Colon Cancer Tissue and Serum Carcinoembryonic Antigen Levels at Initial Surgery and Recurrence.
    Saito G; Sadahiro S; Okada K; Tanaka A; Suzuki T; Kamijo A
    Oncology; 2016; 91(2):85-9. PubMed ID: 27260164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of serum tumor markers in the management of patients with malignancy.
    Markman M
    J Cancer Res Clin Oncol; 1993; 119(11):635-6. PubMed ID: 7688748
    [No Abstract]   [Full Text] [Related]  

  • 12. Prostate cancer: estimating the benefits of PSA screening.
    Vickers AJ; Lilja H
    Nat Rev Urol; 2009 Jun; 6(6):301-3. PubMed ID: 19498406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CEA for monitoring colon cancer.
    Cohen AM; Paty P
    JAMA; 1994 Feb; 271(5):346; author reply 346-7. PubMed ID: 8283580
    [No Abstract]   [Full Text] [Related]  

  • 14. CEA for monitoring colon cancer.
    Corman M; Prager ED
    JAMA; 1994 Feb; 271(5):346; author reply 346-7. PubMed ID: 8283581
    [No Abstract]   [Full Text] [Related]  

  • 15. Distributions in CEA doubling time differ in patients with recurrent colorectal carcinomas.
    Yamamoto M; Maehara Y; Sakaguchi Y; Mine H; Yamanaka T; Korenaga D; Okamura T
    Hepatogastroenterology; 2004; 51(55):147-51. PubMed ID: 15011851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prostate cancer screening: no proof of the benefit].
    Laplanche A; Hill C
    Presse Med; 2009 Oct; 38(10):1393-5. PubMed ID: 19647979
    [No Abstract]   [Full Text] [Related]  

  • 17. Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer.
    Tarle M
    Anticancer Res; 1993; 13(3):769-77. PubMed ID: 7686362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recrudescent prostate cancer with a low serum PSA level and a high serum CEA level treated with docetaxel : a case report].
    Fujita M; Goto T; Uchida K; Saiki S; Arima R
    Hinyokika Kiyo; 2013 Mar; 59(3):183-8. PubMed ID: 23633635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early-stage prostate cancer, PSA screening rates decline.
    Printz C
    Cancer; 2016 Mar; 122(6):825. PubMed ID: 26938268
    [No Abstract]   [Full Text] [Related]  

  • 20. [Elevated PSA--what to do?].
    Machemer H; Rohde D
    MMW Fortschr Med; 2008 Oct; 150(44):38-9. PubMed ID: 19024490
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.